Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
BIO-RAD LABORATORIES, INC.
Bear Case (25th pct.)
-47.3% vs price
Base Case (Median)
-38.0% vs price
Bull Case (75th pct.)
1.0% vs price
◇ = Current price | | Bear | Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| PE Comparable | $183.90 | -50.2% | Medium (25%) |
| Growth Trajectory DCF | $456.44 | 23.6% | Medium (20%) |
| Graham Number | $226.61 | -38.6% | Medium (40%) |
| EV/EBITDA | $419.79 | 13.7% | Medium (20%) |
| EV/FCF | $231.47 | -37.3% | Medium (20%) |
| Earnings Power Value | $32.83 | -91.1% | Medium (50%) |
Based on 6 out of 7 methods, BIO appears fairly valued at the current price of $369.14. The base case fair value of $229.04 implies 38.0% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.